Among all neurodegenerative diseases, Alzheimer's Disease (AD) is the most prevalent worldwide, with a huge burden to the society and no efficient AD treatment so far. Continued efforts have been being made towards early and powerful diagnosis of AD, in the hope for a successful set of clinical trials and subsequently AD curative treatment. Towards this aim, detection and quantification of amyloid beta (Aβ) peptides in cerebrospinal fluid (CSF) and other biofluids, which are established and validated biomarkers for AD, have drawn attention of the scientific community and industry over almost two decades. In this work, an overview on our major contributions over 15 years to develop different electrokinetic and microfluidic strategies for Aβ peptides detection and quantification is reported. Accordingly, discussions and viewpoints on instrumental and methodological developments for microscale electrophoresis, microfluidic designs and immuno‐enrichment / assays on magnetic beads in microchannels for tracing Aβ peptides in CSF are given in this review.

中文翻译：

---

淀粉样β肽生物标志物检测的最新电动和微流策略：阿尔茨海默氏病的分子诊断

在所有的神经退行性疾病中，阿尔茨海默氏病（AD）是世界上最流行的疾病，给社会带来了沉重的负担，迄今为止尚无有效的AD治疗方法。为了早期成功进行AD的强有力的诊断，人们一直在努力，希望能够成功进行一系列的临床试验并随后进行AD的治疗。为了实现这一目标，已经建立并验证了AD的生物标记物的脑脊髓液（CSF）和其他生物流体中的淀粉样β（Aβ）肽的检测和定量已经引起了科学界和工业界近二十年来的关注。在这项工作中，概述了我们在15年中为开发不同的电动和微流控策略以检测和定量Aβ肽所做的主要贡献。因此，